

Sara Gutierrez-Enrquez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3214860/sara-gutierrez-enriquez-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

1,844
citations

23
h-index

41
g-index

77
ext. papers

2,384
ext. citations

4.6
avg. IF

3.58
L-index

#	Paper	IF	Citations
71	Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100890	3.3	0
70	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).. <i>Lung Cancer</i> , 2022 , 166, 228-241	5.9	0
69	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. <i>Cancer Research</i> , 2022 , 82, 1646-1657	10.1	4
68	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. <i>Npj Breast Cancer</i> , 2021 , 7, 52	7.8	2
67	First international workshop of the ATM and cancer risk group (4-5 December 2019). <i>Familial Cancer</i> , 2021 , 1	3	5
66	Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes. <i>Cancers</i> , 2021 , 13,	6.6	3
65	A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients. <i>Clinical Chemistry</i> , 2021 , 67, 518-533	5.5	1
64	The computational approach to variant interpretation 2021 , 89-119		0
63	A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy. <i>Computers in Biology and Medicine</i> , 2021 , 135, 104624	7	
62	Clinical consequences of BRCA2 hypomorphism. <i>Npj Breast Cancer</i> , 2021 , 7, 117	7.8	0
61	BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients. <i>Cancer Genetics</i> , 2021 , 258-259, 10-17	2.3	1
60	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020 , 10, 575909	5.3	5
59	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020 , 10, 575909	5.3	1
58	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019 , 40, 1557-1578	4.7	52
57	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019 , 138, 59-67	5.3	26
56	BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge. <i>Human Mutation</i> , 2019 , 40, 1593-1611	4.7	4
55	Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. <i>International Journal of Cancer</i> , 2019 , 145, 2682-2691	7.5	21

54	Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants. <i>Human Mutation</i> , 2019 , 40, 1546-1556	4.7	13
53	Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes. <i>Human Mutation</i> , 2019 , 40, 2296-2317	4.7	6
52	Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 543-550	4.4	5
51	Screening of deep intronic regions by targeted gene sequencing identifies the first germline variant causing pseudoexon activation in a patient with breast/ovarian cancer. <i>Journal of Medical Genetics</i> , 2019 , 56, 63-74	5.8	16
50	Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. <i>International Journal of Cancer</i> , 2019 , 145, 401-414	7.5	14
49	Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1. <i>Nature Communications</i> , 2018 , 9, 967	17.4	23
48	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 1203-1210	10.3	160
47	Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?. <i>Frontiers in Genetics</i> , 2018 , 9, 366	4.5	35
46	Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 2495-2513	4.9	31
45	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	85
44	BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. <i>Human Mutation</i> , 2018 , 39, 2025-2039	4.7	12
43	Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G>T as a case study. <i>Human Mutation</i> , 2018 , 39, 1155-1160	4.7	5
42	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2240-2250	2.2	101
41	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016 , 121, 431-439	5.3	69
40	Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. <i>Clinical and Translational Oncology</i> , 2016 , 18, 981-7	3.6	16
39	Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. <i>Journal of Medical Genetics</i> , 2016 , 53, 548-58	5.8	37
38	Apoptosis for prediction of radiotherapy late toxicity: lymphocyte subset sensitivity and potential effect of TP53 Arg72Pro polymorphism. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 371-82	5.4	10
37	Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31 BRCA2 genetic variants. <i>Human Mutation</i> , 2014 , 35, 53-7	4.7	16

36	RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 133-43	4.4	23
35	Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. <i>Clinical Chemistry</i> , 2014 , 60, 341-52	5.5	53
34	About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. <i>International Journal of Cancer</i> , 2014 , 134, 2088-97	7.5	21
33	Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 3666-80	5.6	60
32	Mutation analysis of the SHFM1 gene in breast/ovarian cancer families. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 529-32	4.9	4
31	Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families. <i>Gynecologic Oncology</i> , 2013 , 131, 460-3	4.9	3
30	Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. <i>PLoS ONE</i> , 2013 , 8, e67538	3.7	35
29	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2012 , 105, 289-95	5.3	52
28	Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 1009-23	4.4	51
27	Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 273-83	4.4	11
26	Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer. <i>Oncology Letters</i> , 2011 , 2, 1287-1289	2.6	8
25	Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 611-22	4.4	17
24	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 671-9	4.4	21
23	Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 705-16	4.4	36
22	Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 573-9	4.4	6
21	A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 221-5	4.4	7
20	Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 587-90	4.4	3
19	Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. <i>Familial Cancer</i> , 2010 , 9, 187-91	3	19

18	The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 461-5	4.4	8
17	ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. <i>Clinical Genetics</i> , 2008 , 73, 465-73	4	17
16	Mitotic delay in lymphocytes from BRCA1 heterozygotes unable to reduce the radiation-induced chromosomal damage. <i>DNA Repair</i> , 2008 , 7, 1907-11	4.3	10
15	Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 455-7	4.4	10
14	Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 103-7	4.4	38
13	Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5035-6; author reply 5036-8	2.2	14
12	Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. <i>Clinical Chemistry</i> , 2006 , 52, 1480-5	5.5	54
11	Re: correspondence from Dr. Michael Swift, Disease Insight Research Foundation, concerning Gutiérrez-Enruez S, Fernet M, Dek T, Bremer M, Lauge A, Stoppa-Lyonnet D, Moullan N, Ange S, Hall J, Functional consequences of the ATM sequence variants for chromosomal radiosensitivity. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 262-263	5	
10	A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. <i>Oncogene</i> , 2004 , 23, 1954-6	9.2	162
9	Functional consequences of ATM sequence variants for chromosomal radiosensitivity. <i>Genes Chromosomes and Cancer</i> , 2004 , 40, 109-19	5	69
8	Use of the cytokinesis-block micronucleus assay to measure radiation-induced chromosome damage in lymphoblastoid cell lines. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2003 , 535, 1-13	3	26
7	A follow-up study on micronucleus frequency in Spanish agricultural workers exposed to pesticides. <i>Mutagenesis</i> , 2002 , 17, 79-82	2.8	29
6	Cytogenetic analysis of Greek farmers using the micronucleus assay in peripheral lymphocytes and buccal cells. <i>Mutagenesis</i> , 2001 , 16, 539-45	2.8	47
5	Low sensitivity of the sister chromatid exchange assay to detect the genotoxic effects of radioiodine therapy. <i>Mutagenesis</i> , 1999 , 14, 221-6	2.8	8
4	Application of the single cell gel electrophoresis (SCGE) assay to the detection of DNA damage induced by 131I treatment in hyperthyroidism patients. <i>Mutagenesis</i> , 1998 , 13, 95-8	2.8	20
3	Comparative study of chromosome aberrations induced with aphidicolin in women affected by breast cancer and cervix uterine cancer. <i>Cancer Genetics and Cytogenetics</i> , 1997 , 94, 120-4		14
2	Telomeric association in women with breast and uterine cervix cancer. <i>Cancer Genetics and Cytogenetics</i> , 1997 , 98, 115-8		7
1	A cytogenetic follow-up study of thyroid cancer patients treated with 131I. <i>Cancer Letters</i> , 1995 , 91, 199-204	2.4	21

